Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. - Test2 - elhamkhani - TriplyDB

Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

http://www.wikidata.org/entity/Q30496234

about

Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice.Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages Cell-mediated drug delivery.Identifying early inflammatory changes in monocyte-derived macrophages from a population with IQ-discrepant episodic memory.Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS.Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease Inflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration?Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.An update on gene therapy in Parkinson's disease.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.Genetic approaches to study glial cells in the rodent brain.The immunological challenges of cell transplantation for the treatment of Parkinson's disease.The role of glia in α-synucleinopathies.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Neuropharmacologic Approaches to Restore the Brain's Microenvironment.Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells.Differentiation of human and murine induced pluripotent stem cells to microglia-like cells.Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases.A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons.Macrophage LXRα gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice.Differential contribution of microglia and monocytes in neurodegenerative diseases.GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.Effect of GDNF on Morphology, Proliferation, and Phagocytic Activity of Rat Neonatal Cortex Isolated Microglia Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease

P2860

Q21133553-A30CE824-13A5-4053-A186-3452AAC850F4 Q26773064-37EFD353-9C8E-44EC-A37D-3C573333B95F Q28543023-5F0C42DF-021C-453B-8A0F-1E33FAC26D72 Q34140861-3DD1C5E2-05C8-4463-A876-B59987585736 Q34476803-FA040495-7684-4D90-BE08-78B24D483BEA Q34632979-16413915-C813-4C35-8057-1D0859677FE3 Q34709440-02CEFBD7-B85E-44EB-940A-CABFE55CB87D Q34721095-F1289E4A-0765-4706-815A-8DDC9B6B7F62 Q35088011-FB36C05F-0070-4291-98CD-92D88CA50178 Q35194750-A0EBB130-0FAE-4F20-AD5E-C656F813EA94 Q35632000-A87A2179-3123-418D-B09C-3FD23AD398DC Q36048615-DE9C4DDC-8AB0-46A3-944F-83CD0CE9C63D Q36055556-599DC693-D354-4094-8DFE-B694D9C8FE26 Q36819317-AEF303A8-B125-4729-B7BE-41606413504A Q37003565-8D70D9E5-793C-469E-BF43-368B7EDF9D45 Q37710820-5CC63299-0465-4809-ADED-2865F151BD14 Q37863587-56432CAE-2EF1-4FD6-B501-B95BD9B4EA21 Q37874476-5343D940-8871-4420-B72C-715792ACCFC6 Q37939514-B95B1A62-96C5-4127-9D19-4BDB5EFE3953 Q37967602-658EADC8-52E3-4668-B41A-A922E6523233 Q38004257-CD361151-9644-4842-98E0-D6D42DB524CF Q38039880-E7BD0DD8-1BF9-4227-8360-EDAE8F3A4D99 Q38112214-A75DA01C-8551-4D86-8977-ADDCD9591C72 Q38879533-0AE29667-F6E2-4F53-A02D-10D54B3B46E2 Q38966488-E0DCDC7E-8331-401E-819C-D3A24C4F8139 Q40311122-B9E60AD5-743D-4AF1-87B0-57B5321E3EC1 Q41605967-D63C0725-BC88-4954-973B-08F9AEBE4B13 Q42712712-8D7EF783-90CA-4CF5-99C0-77D222B172E9 Q45868148-24CDE0B3-E8C8-42EC-808B-61EB619BBCD1 Q48141250-6CC2DCC7-CCB4-412E-A26A-1783DFA33353 Q52721898-D0E4B847-EC95-4F01-ACBB-C6D2258FE925 Q58051763-D3970CA6-F5FE-4D16-98C5-9C8ADE5DD8BB Q59136331-4C063669-0252-40AF-88FC-B8AC7FC08792

P2860

Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

http://www.wikidata.org/entity/Q30496234

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@ast

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@en

type

label

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@ast

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@en

prefLabel

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@ast

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@en

P1433

Q30496234-6575A586-61DB-4BA5-99EB-5679DE827773

P1476

Q30496234-13C9705C-E275-4E6E-944E-AC0E0AB7C9FD

P2093

Q30496234-2066CADD-5A96-4EBD-8EBB-6D088C3CF70A

Q30496234-2778E756-63B2-49DA-B2F1-2CCC82F4C0DA

Q30496234-4B1335EF-AE31-4463-A199-C9A1AB2B8554

Q30496234-7773E73D-C5AF-40A0-B29A-A2FA5587F89C

Q30496234-82494FAD-DF97-4C49-B20C-FB529CF377F0

Q30496234-A3FFBB5C-4DBB-478C-A9D8-65DCD235DB1F

Q30496234-AB40F680-7475-48D9-923F-AA57E5F89E9E

Q30496234-AFCBD95D-7188-4F74-93D0-4DDE2600967D

P2860

Q30496234-00CAC1CE-592E-4748-9838-869E469B3C02

Q30496234-0198C058-F302-4C7D-998C-2A83F0C3ED5B

Q30496234-0B79C52D-9745-47C1-86C5-987DEB310478

Q30496234-0C29B3AE-2661-4AA0-8FBE-0053211C7051

Q30496234-0D3EA966-69C7-4349-BA73-D59A33B93640

Q30496234-19543BD2-9CB8-4C72-9C84-D493D20E084A

Q30496234-1ADBDB9A-DF3A-4119-BDCB-088E4286F4E1

Q30496234-27715933-9F94-4115-BA15-113FA3E38BB2

Q30496234-2E14EEE0-A088-466D-8D3C-807DA11481C6

Q30496234-3237C54E-435F-4DF6-9615-43CF55C978EA

P304

Q30496234-4EB4817D-B24F-4C93-B01F-BF2D5AF55BB4

P31

Q30496234-4667C3CA-92D4-4F72-BF71-DD59F325C4EF

P356

Q30496234-29E34785-ADBA-4D44-AEB2-3757646CF16C

P433

Q30496234-3E6D10D1-DFC5-4EE4-8F07-AD4CA51105CC

P478

Q30496234-8D799027-1214-44C9-A2CA-2258EDC139CC

P577

Q30496234-C413FEE5-CE60-4AC7-93AD-8A8385B4BE40

P5875

Q30496234-CF4D2B0D-C211-4D8D-B6D9-2B9B591EB928

P698

Q30496234-BD10E1C8-3FBE-43BE-8895-59212BD5CCA3

P921

Q30496234-0E3590D2-BCCA-4FC6-B6A4-5A4E587834B8

Q30496234-75C8C859-62CF-4943-B84E-1F35E905FB76

Q30496234-AFFC43D1-B0EB-476A-9B73-AF09BF703396

P932

Q30496234-14C4A697-ABB2-4940-8DCC-5C5D966637C3

P356

P1433

Molecular Therapy

P1476

Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.

@en

P2093

Guiming Li

http://www.w3.org/2001/XMLSchema#string

James L Roberts

http://www.w3.org/2001/XMLSchema#string

Kc Biju

http://www.w3.org/2001/XMLSchema#string

Qing Zhou

http://www.w3.org/2001/XMLSchema#string

Robert A Clark

http://www.w3.org/2001/XMLSchema#string

Senlin Li

http://www.w3.org/2001/XMLSchema#string

Syed Z Imam

http://www.w3.org/2001/XMLSchema#string

William W Morgan

http://www.w3.org/2001/XMLSchema#string

P2860

Functional recovery in parkinsonian monkeys treated with GDNF

Prospects for new restorative and neuroprotective treatments in Parkinson's disease

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

Parkinson's disease: mechanisms and models

Ageing and Parkinson's disease: substantia nigra regional selectivity

Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator

Correction of sickle cell disease in transgenic mouse models by gene therapy.

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.

Microglia: activation and their significance in the central nervous system.

Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

P304

1536-1544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.107

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44657095

http://www.w3.org/2001/XMLSchema#string

P698

20531393

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2927058

http://www.w3.org/2001/XMLSchema#string